A 25-Study Review Finds Methadone's Heart Risk Doesn't Wait for High Doses

Methadone has treated opioid addiction in the United States since the 1960s, and it remains the medication requiring the most infrastructure: a licensed clinic, witnessed dosing, urine testing, and — in principle — a cardiac workup. A systematic review published October 15 in BMC Pharmacology and Toxicology argues that last part deserves more attention.

The review, led by Kamaledin Alaedini Shoormasti and Zahra Behroozi at Iran's Mazandaran University of Medical Sciences, pooled 25 studies from Embase, PubMed and Scopus through 2025 under PRISMA guidelines, scoring each with the STROBE checklist. Heterogeneity was large enough that the authors abandoned meta-analysis and wrote a narrative synthesis instead.

The synthesis adds no new mechanism, only a firmer shape for an old concern. The evidence consistently associates methadone maintenance with QTc prolongation, the slowed cardiac repolarization that can tip into a dangerous arrhythmia. The effect appears dose-related, is more pronounced in women and in patients taking other medications — benzodiazepines in particular — and several included studies reported prolongation at doses that would not raise an eyebrow in a typical clinic.

What the Label Already Says

None of this is news to the Food and Drug Administration. Methadone's oral labeling carries a boxed warning titled, in part, "Life-Threatening QT Prolongation," and section 5.3 opens with the observation that QT prolongation and serious arrhythmia have been seen during treatment. The label notes that methadone inhibits cardiac potassium channels and lists the risk factors clinicians are told to watch: cardiac hypertrophy, diuretic use, low potassium, low magnesium, a history of conduction abnormalities, and concurrent drugs that affect cardiac conduction.

The label also concedes its own blind spots. Methadone in patients who already have a prolonged QT interval "has not been systematically studied." For a medication prescribed largely to people with disrupted primary care and years of stimulant use, that is a substantial gap.

The Gap Between the Label and the Clinic

The review's practical argument lands on monitoring. An ECG before initiation and after significant dose changes is the standard of care on paper, and unevenly delivered in practice: a baseline tracing costs money, needs a machine and a reader, and competes with everything else a clinic does in a dosing window.

That gap has widened structurally. Federal rules finalized in 2024 loosened take-home dosing schedules, meaning fewer in-person visits for stable patients — precisely the population least likely to sit in a clinic long enough for anyone to notice palpitations. Remote dosing helps retention in medication-assisted treatment, and it also removes the informal observation that used to catch things.

The authors stop short of a specific monitoring protocol, which is honest and unhelpful in equal measure. They say risk assessment should be individualized and cardiac monitoring careful, particularly for women and anyone whose regimen includes a benzodiazepine.

The counterweight matters as much as the warning. Methadone is the medication that holds a large share of patients with opioid use disorder in treatment when buprenorphine has failed or is unavailable, and untreated opioid use disorder carries an overdose risk that dwarfs the arrhythmia risk in most patients. Nothing in this review supports stopping methadone. It supports looking at the heart before the next dose increase.

The limits are worth stating: 25 observational studies, wide methodological variation, a narrative synthesis rather than pooled estimates, and an early-access version of record that may still be revised. It establishes direction and consistency, not a threshold number. Clinicians who want a cutoff will not find one here — itself a finding about how thin the dose-response evidence remains for a drug in continuous use for sixty years.